An Independent Validation Study of Candidate microRNAs as
Predictive Biomarkers for Bevacizumab-based Therapy in Patients
With Metastatic Colorectal Cancer

J 2021

An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer

KISS, David; Táňa MACHÁČKOVÁ; Kamila SOUČKOVÁ; Pavel FABIAN; Iveta KŘEPELKOVÁ et. al.

Základní údaje

Originální název

An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer

Autoři

KISS, David; Táňa MACHÁČKOVÁ; Kamila SOUČKOVÁ ; Pavel FABIAN; Iveta KŘEPELKOVÁ; M. SVOBODA a Igor KISS

Vydání

In vivo, ATHENS, Greece : International Institute of Anticancer Research, 2021, 0258-851X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.406

Kód RIV

RIV/00216224:14740/21:00120233

Organizační jednotka

Středoevropský technologický institut

DOI

https://doi.org/10.21873/invivo.12567

UT WoS

000691746000013

EID Scopus

2-s2.0-85113904648

Klíčová slova anglicky

Bevacizumab; metastatic colorectal cancer; microRNA; progression-free survival; predictive biomarker; validation

Štítky

CF GEN, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 15. 10. 2024 14:27, Ing. Martina Blahová

Anotace

V originále

Background/Aim: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous study identified and subsequently validated 4 microRNAs in a small group of patients as predictors of the therapeutic response to bevacizumab combined with chemotherapy. The aim of this follow-up study is to confirm the predictive ability of these tissue miRNAs in a larger independent cohort of mCRC patients. Patients and Methods: The retrospective study included 92 patients with generalized-radically inoperable tumors treated with the combined therapy of bevacizumab/FOLFOX in a standard regimen. Results: Expression levels of candidate miRNA biomarkers (miR-92b3p, miR-3156-5p, miR-10a-5p and miR-125a-5p) were determined in tumor tissue specimens and statistically evaluated. MiR-92b-3p and miR-125a-5p were confirmed to be associated with radiological response according to RECIST criteria (p=0.005 and 0.05, respectively) and to be up-regulated in responders to bevacizumab/FOLFOX therapy. Higher levels of miR-92b-3p were also significantly associated with extended progression-free survival

Návaznosti

NU20-03-00127, projekt VaV

Název: Dlouhé nekódující RNA v exozómech jako biomarkery umožňující neinvazivní časnou detekci kolorektálního karcinomu

Investor: Ministerstvo zdravotnictví ČR, Dlouhé nekódující RNA v exozómech jako biomarkery umožňující neinvazivní časnou detekci kolorektálního karcinomu, Podprogram 1 - standardní

90091, velká výzkumná infrastruktura

Název: NCMG

Citovat

KISS, David; Táňa MACHÁČKOVÁ; Kamila SOUČKOVÁ; Pavel FABIAN; Iveta KŘEPELKOVÁ; M. SVOBODA a Igor KISS. An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer. In vivo. ATHENS: Greece : International Institute of Anticancer Research, 2021, roč. 35, č. 5, s. 2809-2814. ISSN 0258-851X. Dostupné z: https://doi.org/10.21873/invivo.12567.

@article{1837296,
   author = {Kiss, David and Macháčková, Táňa and Součková, Kamila and Fabian, Pavel and Křepelková, Iveta and Svoboda, M. and Kiss, Igor},
   article_location = {ATHENS},
   article_number = {5},
   doi = {https://doi.org/10.21873/invivo.12567},
   keywords = {Bevacizumab; metastatic colorectal cancer; microRNA; progression-free survival; predictive biomarker; validation},
   language = {eng},
   issn = {0258-851X},
   journal = {In vivo},
   title = {An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer},
   url = {https://iv.iiarjournals.org/content/35/5/2809},
   volume = {35},
   year = {2021}
}

TY  - JOUR
ID  - 1837296
AU  - Kiss, David - Macháčková, Táňa - Součková, Kamila - Fabian, Pavel - Křepelková, Iveta - Svoboda, M. - Kiss, Igor
PY  - 2021
TI  - An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer
JF  - In vivo
VL  - 35
IS  - 5
SP  - 2809-2814
EP  - 2809-2814
PB  - Greece : International Institute of Anticancer Research
SN  - 0258851X
KW  - Bevacizumab
KW  - metastatic colorectal cancer
KW  - microRNA
KW  - progression-free survival
KW  - predictive biomarker
KW  - validation
UR  - https://iv.iiarjournals.org/content/35/5/2809
N2  - Background/Aim: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous study identified and subsequently validated 4 microRNAs in a small group of patients as predictors of the therapeutic response to bevacizumab combined with chemotherapy. The aim of this follow-up study is to confirm the predictive ability of these tissue miRNAs in a larger independent cohort of mCRC patients. Patients and Methods: The retrospective study included 92 patients with generalized-radically inoperable tumors treated with the combined therapy of bevacizumab/FOLFOX in a standard regimen. Results: Expression levels of candidate miRNA biomarkers (miR-92b3p, miR-3156-5p, miR-10a-5p and miR-125a-5p) were determined in tumor tissue specimens and statistically evaluated. MiR-92b-3p and miR-125a-5p were confirmed to be associated with radiological response according to RECIST criteria (p=0.005 and 0.05, respectively) and to be up-regulated in responders to bevacizumab/FOLFOX therapy. Higher levels of miR-92b-3p were also significantly associated with extended progression-free survival
ER  -

KISS, David; Táňa MACHÁČKOVÁ; Kamila SOUČKOVÁ; Pavel FABIAN; Iveta KŘEPELKOVÁ; M. SVOBODA a Igor KISS. An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer. \textit{In vivo}. ATHENS: Greece : International Institute of Anticancer Research, 2021, roč.~35, č.~5, s.~2809-2814. ISSN~0258-851X. Dostupné z: https://doi.org/10.21873/invivo.12567.

Přehled o publikaci